AFP
MRNA icon

Ausdal Financial Partners’s Moderna MRNA Stock Holding History

Ausdal Financial Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903K Buy
12,894
+4,045
+46% +$209K 0.04% 442
2026
Q1 		$450K Buy
8,849
+1,540
+21% +$71.8K 0.02% 623
2025
Q4 		$216K Buy
+7,309
New +$199K 0.01% 871
2024
Q3 		– Sell
-1,967
Closed -$234K – 538
2024
Q2 		$234K Buy
+1,967
New +$249K 0.02% 445
2023
Q3 		– Sell
-1,945
Closed -$236K – 451
2023
Q2 		$236K Sell
1,945
-330
-15% -$44K 0.03% 363
2023
Q1 		$349K Buy
2,275
+234
+11% +$38.6K 0.05% 309
2022
Q4 		$367K Buy
+2,041
New +$334K 0.05% 294
2022
Q3 		– Sell
-1,675
Closed -$239K – 466
2022
Q2 		$239K Buy
1,675
+473
+39% +$67.6K 0.04% 388
2022
Q1 		$207K Buy
1,202
+142
+13% +$23.9K 0.03% 445
2021
Q4 		$269K Buy
1,060
+309
+41% +$90.3K 0.04% 392
2021
Q3 		$289K Buy
+751
New +$277K 0.04% 367
2021
Q2 		– Sell
-1,564
Closed -$205K – 482
2021
Q1 		$205K Sell
1,564
-1,994
-56% -$289K 0.03% 413
2020
Q4 		$278K Buy
3,558
+244
+7% +$24.7K 0.05% 325
2020
Q3 		$234K Buy
+3,314
New +$231K 0.06% 303

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Ausdal Financial Partners's MRNA Position: Q2 2026 in Review

Ausdal Financial Partners increased its Moderna (MRNA) stake by 46% in Q2 2026, buying an estimated $209K and bringing the position to 12,894 shares worth $903K. The position accounts for 0.04% of the portfolio, ranked #442.

Ausdal Financial Partners first reported a position in MRNA in Q3 2020 and has held it in 14 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Ausdal Financial Partners held 12,894 shares of Moderna worth $903K as of Q2 2026.
  • Ausdal Financial Partners bought 4,045 Moderna shares in Q2 2026, an estimated $209K.
  • Moderna made up 0.04% of Ausdal Financial Partners's portfolio in Q2 2026, its #442 holding.
  • Ausdal Financial Partners first reported a position in Moderna in Q3 2020 and has held it in 14 quarters since.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ausdal Financial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.